medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2014, Número 2

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2014; 12 (2)


Factor de crecimiento epidérmico: aplicación clínica en dermatología

Gama MAM, Gómez VR, Contreras RJ

Idioma: Español
Referencias bibliográficas: 28
Paginas: 128-132
Archivo PDF: 120.21 Kb.


RESUMEN

Las funciones biológicas y propiedades farmacológicas del factor de crecimiento epidérmico han sido tema de numerosas investigaciones y publicaciones científicas, sobre todo en cuanto a su uso como inductor de la cicatrización de heridas crónicas.
Se realizó una revisión sistemática de una extensa base de datos en línea para identificar la literatura relevante al campo de la dermatología.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Cohen S. “Origins of Growth Factors: NGF and EGF”. J Biol Chem 2008; 283: 3379-3397.

  2. Cohen S. “Purification of a Nerve-Growth Promoting Protein from the mouse salivary gland and its neuro-cytotoxic antiserum”. Proc Natl Acad Sci USA 1960; 46: 302-311.

  3. Cohen S, Elliott GA. “The stimulation of epidermal keratinization by a protein isolated from the submaxillary gland of the mouse”. J Invest Dermatol 1963; 1-5 .

  4. Cohen S. “Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal”. J Biol Chem 1962; 237: 1555-1562.

  5. Carpenter G, Cohen S. “Epidermal Growth Factor”. Ann. Rev. Biochem. 1979; 193-216.

  6. Freedberg I, Tomic-Canic M, Komine M, Blumenberg M. “Keratins and the Keratinocyte Activation Cycle”. J Invest Dermatol 2001; 633-640.

  7. Berlanga-Acosta J, Gavilondo-Cowley J, García D, Martín-Machado J, Guillen-Nieto G. “Epidermal Growth Factor (EGF) and Platelet-Derived Growth Factor (PDGF) as Tissue Healing Agents: Clarifying Concerns about their Possible Role in Malignant Transformation and Tumor Progression”. J Carcinogene Mutagene 2011; 1: 3-11.

  8. Berlanga J. “Heberprot-P: antecedentes experimentales y bases farmacológicas”. Biotecnología Aplicada 2010; 27: 83-87.

  9. Zong X, Jiang D, Wang J, Liu J, Liu Z, Zhen-z, et al. “Keratinocyte growth factor phage model peptides can promote epidermal cell proliferation without tumorigenic effect”. Chin Med J. 2010; 123(9): 1195-1200.

  10. Demidova-Rice T, Hamblin R, Herman I. “Acute and Impaired Wound Healing: Pathophysiology and Current Methods for Drug Delivery, Part 2: Role of Growth Factors in Normal and Pathological Wound Healing: Therapeutic Potential and Methods of Delivery”. Adv Skin Wound Care 2012; 25: 349-370.

  11. Tiaka E, Papanas N, Manolakis A, Georgiadis G. “Epidermal Growth Factor in the Treatment of Diabetic Foot Ulcers: An Update”. Perspect Vasc Surg Endovasc Ther 2012;XX(X): 2-7

  12. Tsang MW, Wong WK, Hung CS, et al. “Human epidermal growth factor enhances healing of diabetic foot ulcers”. Diabetes Care. 2003; 26: 1856-1861.

  13. Viswanathan V, Pendsey S. “A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN-DTM 150) in healing diabetic foot ulcers”. Wounds. 2006; 18: 186-196. ana maría gama méndez y cols. f a c t o r de c r e c imi e n t o e p idé rmi co Dermatología Cosmética, Médica y Quirúrgica DCMQ 132 A R T Í C U L O S D E R E V I S I Ó N Volumen 12 / Número 2 n abril-junio 2014

  14. Tuyet HL, Nguyen Quynh TT, Vo Hoang Minh H, et al. “The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary results”. Int Wound J. 2009; 6: 159-166.

  15. Hong JP, Jung HD, Kim YW. “Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers”. Ann Plast Surg. 2006; 56: 394-398.

  16. Fernández-Montequin J, Valenzuela-Silva C, Gonzalez-Silva O, Savigne W, Sancho-Soutelo L, Rivero-Fernandez F, et al. “Intralesional injection of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcer: a multicenter, randomized, placebo-controlled, double-blind study”. Int Wound J 2009; 6: 432-443.

  17. Fernández-Montequin J, et al. “Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronicdiabetic foot ulcer: treatment up to complete wound closure”. Int Wound J 2009; 6: 67-72.

  18. Fernández-Montequin JI, Infante-Cristia E, Valenzuela-Silva C, et al. “Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation”. Int Wound J 2007;4,333-343.

  19. O’Meara S, Cullum N, Majid M, Sheldon T. “Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration”. Health Technol Assess 2000; 4(21): 1-3.

  20. Acosta JB, Valdez C, Franco N, Alba JS, et al. “Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds”. Int Wound J. 2006; 3: 232-239.

  21. Hong JP, et al. “Recombinant human epidermal growth factor treatment of radiation-induced severe oral mucositis in patients with head and neck malignancies”. Eur J Cancer Care 2009; 18: 636-641.

  22. Haejin OH, et al. “Recombinant Human Epidermal Growth Factor (rhEGF) Protects Radiation-Induced Intestine Injury in Murine System”. J. Radiat. Res. 2010; 535-541.

  23. Berlanga J, et al. “Prophylactic use of epidermal growth factor reduces ischemia/reperfusion intestinal damage”. Am J Pathol 2002; 373-379.

  24. Kim T, Soo Han D, Soo Eun Ch, Woo Chung Y. “Recombinant Human Epidermal Growth Factor Enhances Wound Healing of Pyoderma Gangrenosum in a Patient with Ulcerative Colitis”. Inflamm Bowel Dis 2008; 14: 725-727.

  25. Singh S. “Evidence-based treatments for pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid: A systematic review”. Indian J Dermatol Venereol Leprol 2011; 77: 456-469.

  26. Tabrizi MN, Chams-Davatchi C, Esmaeeli N, Noormohammadpoor P, Safar F, Etemadzadeh H, et al. “Accelerating effects of epidermal growth factor on skin lesions of pemphigus vulgaris: A double-blind, randomized, controlled trial”. J Eur Acad Dermatol Venereol 2007; 21: 79-84.

  27. Tsang M, Tsang K.Y, Keung W, Wong R. “The use of recombinant human epidermal growth factor (RhEGF) in a gentleman with drug-induced Steven Johnson Syndrome”. Dermatol Online J 2004; 10.

  28. Falanga V, Eaglstein WH, Bucalo B, Katz MH, Harris B, Carson P. ”Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers”. J Dermatol Surg Oncol. 1992; 18(7): 604-606.




2020     |     www.medigraphic.com